Pricing Log in Create free account

Climb Bio, Inc. (CLYM) vs Ovid Therapeutics (OVID)

Climb Bio, Inc. and Ovid Therapeutics are both Biotechnology companies. Climb Bio, Inc. and Ovid Therapeutics are of similar size ($509.5M and $503.9M). Climb Bio, Inc. has the higher net margin (0.00% vs −439.1%) and the lower return on invested capital (−71.7% vs −35.1%). Across the 13 metrics below, Climb Bio, Inc. leads on 7 and Ovid Therapeutics on 6.

Valuation

Metric CLYM OVID Biotechnology median
P/E n/m n/m 10.60
P/S n/m 72.14 9.40
P/B 3.27 2.70 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 58.65 9.02
Earnings yield (8.07%) (7.85%) (32.88%)
Free cash flow yield (6.79%) (9.69%) (23.13%)

Profitability

Metric CLYM OVID Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (742.97%) 0.00%
Net margin 0.00% (439.11%) 0.00%
Free cash flow margin 0.00% (697.30%) 0.00%
Return on equity (27.10%) (25.97%) (51.96%)
Return on assets (26.27%) (22.30%) (46.06%)
Return on invested capital (71.73%) (35.11%) 0.00%

Growth

Metric CLYM OVID Biotechnology median
Revenue growth (TTM) — 1,333.39% 6.76%
EPS growth (last fiscal year) 42.48% 37.84% 29.88%
Revenue growth, 5-year CAGR — (10.48%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLYM OVID Biotechnology median
Debt to equity 0.00 0.05 0.00
Current ratio 31.45 12.39 4.97
Net debt to EBITDA 1.44 1.37 1.01

Dividend

Metric CLYM OVID Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CLYM OVID Biotechnology median
Market cap 509.46m 503.87m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack